Magnitude of Osteoarthritis disadVantage on pEoples liveS (MOVES)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01423097
First received: August 24, 2011
Last updated: October 9, 2012
Last verified: October 2012
  Purpose

Estimate the prevalence of self-reported osteoarthritis and its characterization in adults over 45 years of age:

  • Characterization of self-reported patients with OA (socio-demographic, comorbidities, VAS for intensity of pain)
  • Characterization of OA diagnosis in patients with self-reported OA
  • Impact of self-reported OA in the working abilities, quality of life and functionality (SF-12 v2.0)
  • Characterization of treatment approaches (therapeutic and non-therapeutic) for self-reported patients with OA
  • Patient perception of impact of OA in its life and importance given to disease

Condition
Osteoarthritis

Study Type: Observational
Study Design: Observational Model: Ecologic or Community
Time Perspective: Cross-Sectional
Official Title: Magnitude of Osteoarthritis disadVantage on pEoples liveS

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Estimate the prevalence of self-reported osteoarthritis (OA) in adults over 45 years of age by direct interview. [ Time Frame: Single interview at the only one patient contact ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Characterization of self-reported patients with OA by collecting socio-demographic information through direct interview. [ Time Frame: Single interview at the only one patient contact ] [ Designated as safety issue: No ]
  • Characterization of self-reported patients with OA by collecting comorbidities information through direct interview. [ Time Frame: Single interview at the only one patient contact ] [ Designated as safety issue: No ]
  • Characterization of self-reported patients with OA by collecting information for intensity of pain through direct interview. [ Time Frame: Single interview at the only one patient contact ] [ Designated as safety issue: No ]
  • Characterization of OA diagnosis in patients with self-reported OA by direct interview. [ Time Frame: Single interview at the only one patient contact ] [ Designated as safety issue: No ]
  • Impact of self-reported OA in the working abilities, quality of life and functionality using Questionnaire SF-12 v2.0 [ Time Frame: Single interview at the only one patient contact ] [ Designated as safety issue: No ]
  • Patient perception of impact of OA in its life and importance given to disease by direct interview. [ Time Frame: Single interview at the only one patient contact ] [ Designated as safety issue: Yes ]

Enrollment: 1015
Study Start Date: September 2011
Study Completion Date: November 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Detailed Description:

Magnitude of Osteoarthritis disadvantage on peoples lives.

  Eligibility

Ages Eligible for Study:   45 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

community sample

Criteria

Inclusion Criteria:

- Adults over 45 years old with self-reported osteoarthritis

Exclusion Criteria:

- NA

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01423097

Locations
Portugal
Research Site
Queluz Baixo, Barcarena, Portugal
Sponsors and Collaborators
AstraZeneca
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01423097     History of Changes
Other Study ID Numbers: NIS-RPO-XXX-2011/2
Study First Received: August 24, 2011
Last Updated: October 9, 2012
Health Authority: Portugal: Data Protection National Committee

Keywords provided by AstraZeneca:
osteoarthritis symptoms

Additional relevant MeSH terms:
Osteoarthritis
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases

ClinicalTrials.gov processed this record on April 17, 2014